Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502786 · ClinicalTrials.gov registry record · Phase 2
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
A Phase 2 study of Recurrent Osteosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 3
- Study locations
NCT02502786 is a Phase 2 study of Recurrent Osteosarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants, below the 63-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (27% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02502786, a Phase 2 study of Recurrent Osteosarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.
Conditions Studied
Interventions
- DRUG GM-CSF
- BIOLOGICAL humanized anti-GD2 antibody
Study Locations (3)
California
- Children's Hospital of Los Angeles (Data Collection Only) - Los Angeles
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD ANDERSON CANCER CENTER (Data Collection Only) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-07 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02502786
The ClinicalTrials.gov registry entry for NCT02502786 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 63-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (27% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which GM-CSF is the first listed.
NCT02502786 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT02502786 about?
NCT02502786 is a clinical study titled "Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma". The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.
What is the current status of trial NCT02502786?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2015-07. Estimated completion is 2026-07.
What conditions does trial NCT02502786 study?
This clinical trial studies the following conditions: Recurrent Osteosarcoma.
What interventions are being tested in trial NCT02502786?
The interventions under investigation include: GM-CSF (DRUG), humanized anti-GD2 antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT02502786?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02502786 being conducted?
This trial has 3 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
COMPLETED · Phase 2
-
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.